drugset / Trial / NCT02382354

Remifentanil for the I-gel and Laryngeal Mask Airway Insertion

NCT02382354

Phase 4 Completed 41 enrolled Ajou University School of Medicine
RandomizedParallel-groupSingle-blindTreatment

Summary

Structural differences of supraglottic airway devices could influence the different compressive forces in the oropharyngeal cavities, and require different depth of anesthesia. The addition of remifentanil during propofol anesthesia facilitates the insertion of laryngeal mask airway (LMA) with minimal adverse hemodynamic disturbances. This study was designed to determine the effect-site concentration of remifentanil in 50% of patients (EC50) and 95% of patients (EC95) for successful i- gel insertion, and compare those for LMA insertion during propofol target-controlled infusion (TCI).

Timeline

Start
2015-03
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 3 ng/ml
Background Propofol Small molecule 5 ug/ml

Indications

No indication recorded.